BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:20:00 PM | Browse: 967 | Download: 868
Publication Name World Journal of Hepatology
Manuscript ID 9585
Country/Territory France
2014-02-19 09:40
Peer-Review Started
2014-02-19 20:25
To Make the First Decision
2014-04-15 15:13
Return for Revision
2014-04-16 12:08
2014-04-25 05:41
Second Decision
2014-08-31 16:57
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-08-31 17:13
Articles in Press
2014-08-31 17:13
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-09-30 16:20
Publish the Manuscript Online
2014-10-19 20:39
ISSN 1948-5182 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Autobiography
Article Title Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients
Manuscript Source Unsolicited Manuscript
All Author List Delphine Bonnet, Matthieu Guivarch, Emilie Bérard, Jean-Marc Combis, Andre Jean Remy, Andre Glibert, Jean-Louis Payen, Sophie Metivier, Karl Barange, Herve Desmorat, Anaïs Palacin, Florence Nicot, Florence Abravanel and Laurent Alric
Funding Agency and Grant Number
Corresponding Author Laurent Alric, Professor, Internal Medecine, Digestive Department, Pavillon Dieulafoy, CHU Purpan, TSA 40031, Toulouse 31059 cedex, France. alric.l@chu-purpan-toulouse.fr
Key Words Hepatitis C virus; Hepatitis C; Antiviral therapy; Protease inhibitors; Fibroscan; Liver stiffness; Cirrhosis; Boceprevir; Telaprevir; Ribavirin
Core Tip To the best of our knowledge, this study marks the first time that a significant link has been shown between a sustained virological response to triple therapy and the liver stiffness measured by elastography at baseline. We also demonstrate that triple therapy is poorly tolerated. Two factors predict the development of serious adverse events: female gender and an initial platelet count of less than 150000/mm3; these factors facilitate the identification of at-risk patients.
Publish Date 2014-10-19 20:39
Citation Bonnet D, Guivarch M, Bérard E, Combis JM, Remy AJ, Glibert A, Payen JL, Metivier S, Barange K, Desmorat H, Palacin A, Nicot F, Abravanel F, Alric L. Telaprevir- and boceprevir-based tritherapies in real practice for F3-F4 pretreated hepatitis C virus patients. World J Hepatol 2014; 6(9): 660-669
URL http://www.wjgnet.com/1948-5182/full/v6/i9/660.htm
DOI http://dx.doi.org/10.4254/wjh.v6.i9.660
Full Article (PDF) WJH-6-660.pdf
Full Article (Word) WJH-6-660.doc
Manuscript File 9585-Review.docx
Answering Reviewers 9585-Answering reviewers.pdf
Copyright License Agreement 9585-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 9585-Language certificate.pdf
Peer-review Report 9585-Peer review(s).pdf
Scientific Misconduct Check 9585-CrossCheck.jpg
Scientific Editor Work List 9585-Scientific editor work list.pdf